12A-1130319
USP patent pending
The MYC signaling pathway plays as important role in the tumorigenesis and progression of cancer. Therefore, comprehensively deciphering the critical lncRNAs that functionally crosstalk with MYC ubiquitination and regulate MYC protein expression and stability may offer novel therapeutic strategies. A novel genome-wide CRISPR activation technology combined with a powerful GPS-EGFP-MYC reporter was used to identify a new lncRNAs lnc00707 that regulates MYC protein stability. Pharmacological inactivation of lnc00707 by Nanoparticle- Gapmer Antisense Oligonucleotide (NP-ASO) not only drastically decreases the tumor growth in both orthotopic preclinical mouse model and patient derived organoid systems, but also enhances CD3+T cell activity in the co-culture system, highlighting the tremendous therapeutic potential of ta novel RNA-based therapy for both targeted and cancer immunotherapy.
- We tested ASOs targeting LNC on MYC protein stablility
- The ASO in this invention not only reduced cancer cell progression, but also promote anti-tumor immunity
- The ASO in this invention was delivered in the nanoparticle by intraperitoneal injection and inhibited tumor progression
- Regulation of LNC and MYC signaling pathway
- Hepatocellular carcinoma targeted drug therapy
- Relationship between lncRNAs and the etiology of several cancers
Yu-Ru Lee
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Antisense Oligonucleotide (ASO) Reduces Tumorigenesis and Promotes Anti-tumor Immunity